FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to immunoglobulins, which specifically bind to matrix metal-proteinase 13 (hereinafter – MMP13); it can be used in medicine for the treatment and prevention of diseases or disorders in an individual, which are related to MMP13 activity.
EFFECT: proposed polypeptides including at least 1 immunoglobulin single variable domain (ISVD) binding to matrix metal-proteinase 13 are MMP13 antagonists with improved preventive, therapeutic, and/or pharmacological properties, including a safer profile compared to comparative molecules.
45 cl, 4 dwg, 28 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDES BINDING TO ADAMTS5, MMP13, AND AGGRECAN | 2018 |
|
RU2786659C2 |
| ADVANCED SERUM ALBUMIN BINDING AGENTS | 2018 |
|
RU2797270C2 |
| ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
| IMPROVED SUBSTANCES BINDING TO SERUM ALBUMIN | 2018 |
|
RU2789495C2 |
| IMPROVED SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS BINDING TO SERUM ALBUMIN | 2017 |
|
RU2765384C2 |
| PD1/CTLA4-BINDING SUBSTANCES | 2016 |
|
RU2755724C2 |
| IMPROVED TNF-BINDING AGENTS | 2016 |
|
RU2774823C2 |
| IMPROVED VARIABLE DOMAINS OF IMMUNOGLOBULINS | 2015 |
|
RU2746738C2 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
| IMMUNOGLOBULINS BINDING AGGRECAN | 2018 |
|
RU2771818C2 |
